CODX: Co-Diagnostics, Inc. Stock

by  •  • Comments Off on CODX: Co-Diagnostics, Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 37.51
Enterprise Value ($M) 22.59
Book Value ($M) 86.01
Book Value / Share 2.75
Price / Book 0.44
NCAV ($M) 52.83
NCAV / Share 1.69
Price / NCAV 0.71

Profitability (mra)
Return on Invested Capital (ROIC) -0.40
Return on Assets (ROA) -0.30
Return on Equity (ROE) -0.32

Liquidity (mrq)
Quick Ratio 10.52
Current Ratio 10.81

Balance Sheet (mrq) ($M)
Current Assets 62.14
Assets 95.32
Liabilities 9.31
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6.81
Operating Income -42.71
Net Income -35.33
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -22.08
Cash from Investing 15.39
Cash from Financing -1.36

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 5.82 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSU
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT T
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SEC
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SE

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 15,839 61,341 25.82
2024-05-02 1,545 32,645 4.73
2024-05-01 1,604 27,200 5.90
2024-04-30 19,217 14,483 132.69
2024-04-29 31,622 16,916 186.94

(click for more detail)

Similar Companies
CHEK – Check-Cap Ltd. CLPT – ClearPoint Neuro, Inc.
COCH – Envoy Medical, Inc. CTCX – Carmell Corporation
CTSO – Cytosorbents Corporation


Financial data and stock pages provided by
Fintel.io